Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
Index- P/E218.04 EPS (ttm)0.72 Insider Own6.82% Shs Outstand55.77M Perf Week-8.39%
Market Cap8.76B Forward P/E75.93 EPS next Y2.07 Insider Trans-0.77% Shs Float51.97M Perf Month-20.12%
Income41.58M PEG12.14 EPS next Q0.30 Inst Own105.06% Short Float9.18% Perf Quarter-11.73%
Sales638.76M P/S13.72 EPS this Y-16.68% Inst Trans1.47% Short Ratio8.76 Perf Half Y10.27%
Book/sh35.35 P/B4.45 EPS next Y41.93% ROA1.55% Short Interest4.77M Perf Year-8.33%
Cash/sh13.47 P/C11.66 EPS next 5Y17.96% ROE2.14% 52W Range110.45 - 211.13 Perf YTD-12.60%
Dividend Est.- P/FCF116.96 EPS past 5Y15.08% ROI1.59% 52W High-25.57% Beta1.04
Dividend TTM- Quick Ratio5.75 Sales past 5Y31.42% Gross Margin44.49% 52W Low42.27% ATR (14)5.91
Dividend Ex-Date- Current Ratio7.02 EPS Y/Y TTM-77.69% Oper. Margin9.71% RSI (14)24.81 Volatility4.19% 3.08%
Employees1783 Debt/Eq0.36 Sales Y/Y TTM-20.31% Profit Margin6.51% Recom1.54 Target Price210.98
Option/ShortYes / Yes LT Debt/Eq0.32 EPS Q/Q-153.51% Payout0.00% Rel Volume0.71 Prev Close157.06
Sales Surprise-8.57% EPS Surprise1.29% Sales Q/Q-16.61% EarningsMay 01 BMO Avg Volume544.60K Price157.14
SMA20-11.43% SMA50-17.01% SMA200-7.55% Trades Volume386,770 Change0.05%
Date Action Analyst Rating Change Price Target Change
Dec-04-23Downgrade The Benchmark Company Buy → Hold
Jul-20-23Initiated Wells Fargo Overweight $185
Jul-05-23Resumed JP Morgan Overweight $220
Mar-28-23Initiated The Benchmark Company Buy $230
Dec-14-22Initiated Deutsche Bank Hold $180
Dec-07-22Initiated RBC Capital Mkts Sector Perform $190
Jul-20-22Initiated UBS Buy $213
Oct-14-21Initiated Exane BNP Paribas Outperform $330
Nov-10-20Initiated KeyBanc Capital Markets Overweight $241
Aug-24-20Reiterated H.C. Wainwright Buy $151 → $168
Apr-17-24 07:30AM
Apr-12-24 10:07AM
Mar-19-24 07:30AM
Mar-12-24 01:18AM
02:02AM Loading…
Feb-27-24 02:02AM
Feb-24-24 12:03AM
Feb-22-24 11:24AM
Feb-21-24 08:45AM
Feb-07-24 07:30AM
Jan-31-24 12:10PM
05:09AM Loading…
Jan-29-24 05:09AM
Dec-19-23 07:30AM
Dec-18-23 04:49AM
Dec-07-23 07:30AM
Nov-30-23 11:31AM
Nov-15-23 07:15AM
Nov-14-23 02:01PM
Nov-07-23 07:30AM
Nov-02-23 07:30AM
Nov-01-23 12:10PM
Oct-31-23 09:41AM
08:50AM Loading…
Oct-25-23 10:01AM
Oct-24-23 10:00AM
Oct-17-23 11:44AM
Oct-02-23 07:30AM
Sep-27-23 06:51AM
Sep-26-23 12:41PM
Sep-14-23 10:10AM
Sep-12-23 07:30AM
Sep-06-23 03:06AM
Sep-01-23 12:19PM
Aug-21-23 06:53AM
Aug-17-23 08:00AM
Aug-10-23 09:39AM
Aug-09-23 06:10AM
Aug-03-23 11:19AM
Aug-02-23 08:55AM
Jul-31-23 09:08AM
Jul-26-23 10:02AM
Jul-25-23 11:40AM
Jul-20-23 10:01AM
Jul-19-23 07:30AM
Jul-10-23 08:34AM
Jun-30-23 10:54AM
Jun-21-23 08:00PM
Jun-07-23 11:30AM
Jun-02-23 11:31AM
Jun-01-23 11:31AM
May-31-23 07:30AM
May-30-23 12:09PM
May-09-23 05:52PM
May-03-23 01:20PM
May-02-23 11:36PM
May-01-23 07:43AM
Apr-26-23 08:00PM
Apr-25-23 02:07PM
Apr-18-23 07:30AM
Apr-11-23 02:41PM
Mar-24-23 11:30AM
Mar-14-23 07:30AM
Feb-23-23 06:28PM
Feb-22-23 08:55AM
Feb-20-23 06:34AM
Feb-09-23 07:30AM
Feb-08-23 07:30AM
Jan-21-23 09:51AM
Jan-19-23 03:10AM
Jan-13-23 08:30AM
Jan-12-23 05:00PM
Jan-03-23 07:30AM
Dec-21-22 10:56AM
Dec-19-22 09:02AM
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KURIYEL RALFSenior VP, R&DMar 11 '24Option Exercise86.101,271109,43327,777Mar 12 08:24 PM
KURIYEL RALFSenior VP, R&DMar 11 '24Sale193.733,517681,34824,260Mar 12 08:24 PM
Hunt AnthonyChief Executive OfficerMar 08 '24Option Exercise16.55117201,956Mar 11 07:43 PM
Hunt AnthonyChief Executive OfficerMar 08 '24Sale197.4416,7073,298,632185,249Mar 11 07:43 PM
DAWES KAREN ADirectorFeb 27 '24Option Exercise42.074,626194,61688,367Feb 28 09:56 PM
DAWES KAREN ADirectorFeb 27 '24Sale193.351,000193,35087,367Feb 28 09:56 PM
Bylund JamesChief Operating OfficerFeb 23 '24Option Exercise94.3394088,67018,508Feb 26 08:38 PM
Bylund JamesChief Operating OfficerFeb 23 '24Sale198.084,373866,20414,135Feb 26 08:38 PM
Gebski ChristineSee RemarksNov 10 '23Sale147.133,788557,32828,787Nov 13 05:10 PM
DAWES KAREN ADirectorAug 29 '23Option Exercise18.127,392133,94384,591Aug 30 04:06 PM
DAWES KAREN ADirectorAug 29 '23Sale171.38850145,67383,741Aug 30 04:06 PM
Madaus Martin DDirectorMay 08 '23Buy156.1850078,0901,611May 08 09:15 PM
Madaus Martin DDirectorMay 05 '23Buy159.1950079,5951,111May 08 09:15 PM
Madaus Martin DDirectorMay 04 '23Buy161.1550080,575611May 08 09:15 PM